140 related articles for article (PubMed ID: 19568884)
1. Diagnostic tumor marker of asbestos-related mesothelioma.
Hino O; Maeda M
Environ Health Prev Med; 2008 Mar; 13(2):71-4. PubMed ID: 19568884
[TBL] [Abstract][Full Text] [Related]
2. Molecular tumor markers for asbestos-related mesothelioma: serum diagnostic markers.
Maeda M; Hino O
Pathol Int; 2006 Nov; 56(11):649-54. PubMed ID: 17040286
[TBL] [Abstract][Full Text] [Related]
3. Establishment of a novel specific ELISA system for rat N- and C-ERC/mesothelin. Rat ERC/mesothelin in the body fluids of mice bearing mesothelioma.
Hagiwara Y; Hamada Y; Kuwahara M; Maeda M; Segawa T; Ishikawa K; Hino O
Cancer Sci; 2008 Apr; 99(4):666-70. PubMed ID: 18294289
[TBL] [Abstract][Full Text] [Related]
4. Sensitive and specific new enzyme-linked immunosorbent assay for N-ERC/mesothelin increases its potential as a useful serum tumor marker for mesothelioma.
Shiomi K; Hagiwara Y; Sonoue K; Segawa T; Miyashita K; Maeda M; Izumi H; Masuda K; Hirabayashi M; Moroboshi T; Yoshiyama T; Ishida A; Natori Y; Inoue A; Kobayashi M; Sakao Y; Miyamoto H; Takahashi K; Hino O
Clin Cancer Res; 2008 Mar; 14(5):1431-7. PubMed ID: 18316566
[TBL] [Abstract][Full Text] [Related]
5. Establishment of the enzyme-linked immunosorbent assay system to detect the amino terminal secretory form of rat Erc/Mesothelin.
Nakaishi M; Kajino K; Ikesue M; Hagiwara Y; Kuwahara M; Mitani H; Horikoshi-Sakuraba Y; Segawa T; Kon S; Maeda M; Wang T; Abe M; Yokoyama M; Hino O
Cancer Sci; 2007 May; 98(5):659-64. PubMed ID: 17425688
[TBL] [Abstract][Full Text] [Related]
6. The utility of serum N-ERC/mesothelin as a biomarker of ovarian carcinoma.
Saeki H; Hashizume A; Izumi H; Suzuki F; Ishi K; Nojima M; Maeda M; Hino O
Oncol Lett; 2012 Oct; 4(4):637-641. PubMed ID: 23205076
[TBL] [Abstract][Full Text] [Related]
7. Mapping and determination of the cDNA sequence of the Erc gene preferentially expressed in renal cell carcinoma in the Tsc2 gene mutant (Eker) rat model.
Yamashita Y; Yokoyama M; Kobayashi E; Takai S; Hino O
Biochem Biophys Res Commun; 2000 Aug; 275(1):134-40. PubMed ID: 10944454
[TBL] [Abstract][Full Text] [Related]
8. Blood tests for asbestos-related mesothelioma.
Maeda M; Hino O
Oncology; 2006; 71(1-2):26-31. PubMed ID: 17344668
[TBL] [Abstract][Full Text] [Related]
9. Mesothelin-related predictive and prognostic factors in malignant mesothelioma: a nested case-control study.
Roe OD; Creaney J; Lundgren S; Larsson E; Sandeck H; Boffetta P; Nilsen TI; Robinson B; Kjaerheim K
Lung Cancer; 2008 Aug; 61(2):235-43. PubMed ID: 18281122
[TBL] [Abstract][Full Text] [Related]
10. Bisecting-GlcNAc on Asn388 is characteristic to ERC/mesothelin expressed on epithelioid mesothelioma cells.
Fujihira H; Takakura D; Matsuda A; Abe M; Miyazaki M; Nakagawa T; Kajino K; Denda-Nagai K; Noji M; Hino O; Irimura T
J Biochem; 2021 Oct; 170(3):317-326. PubMed ID: 33792699
[TBL] [Abstract][Full Text] [Related]
11. MESOMARK kit detects C-ERC/mesothelin, but not SMRP with C-terminus.
Segawa T; Hagiwara Y; Ishikawa K; Aoki N; Maeda M; Shiomi K; Hino O
Biochem Biophys Res Commun; 2008 May; 369(3):915-8. PubMed ID: 18328258
[TBL] [Abstract][Full Text] [Related]
12. Secretion of N-ERC/mesothelin and expression of C-ERC/mesothelin in human pancreatic ductal carcinoma.
Inami K; Kajino K; Abe M; Hagiwara Y; Maeda M; Suyama M; Watanabe S; Hino O
Oncol Rep; 2008 Dec; 20(6):1375-80. PubMed ID: 19020717
[TBL] [Abstract][Full Text] [Related]
13. Serum Levels of N- and C-ERC/Mesothelin and Clinicopathological Factors in Mesothelioma Patients and Those without Mesothelioma.
Koyanagi AI; Kajino K; Nojiri S; Abe M; Kobayashi T; Sugitani Y; Yue L; Ohtsuji N; Arakawa A; Sato T; Takahashi K; Suzuki K; Orimo A; Yao T; Hino O
Juntendo Iji Zasshi; 2023; 69(2):124-136. PubMed ID: 38854453
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of mesothelin family proteins and osteopontin for malignant mesothelioma.
Pantazopoulos I; Boura P; Xanthos T; Syrigos K
Eur Respir J; 2013 Mar; 41(3):706-15. PubMed ID: 22835614
[TBL] [Abstract][Full Text] [Related]
15. Serum level of expressed in renal carcinoma (ERC)/ mesothelin in rats with mesothelial proliferative lesions induced by multi-wall carbon nanotube (MWCNT).
Sakamoto Y; Dai N; Hagiwara Y; Satoh K; Ohashi N; Fukamachi K; Tsuda H; Hirose A; Nishimura T; Hino O; Ogata A
J Toxicol Sci; 2010 Apr; 35(2):265-70. PubMed ID: 20371980
[TBL] [Abstract][Full Text] [Related]
16. ERC/mesothelin as a marker for chemotherapeutic response in patients with mesothelioma.
Tajima K; Hirama M; Shiomi K; Ishiwata T; Yoshioka M; Iwase A; Iwakami S; Yamazaki M; Toba M; Tobino K; Sugano K; Ichikawa M; Hagiwara Y; Takahashi K; Hino O
Anticancer Res; 2008; 28(6B):3933-6. PubMed ID: 19192652
[TBL] [Abstract][Full Text] [Related]
17. Significance of serum mesothelin in an asbestos-exposed population in the Czech Republic.
Jakubec P; Pelclova D; Smolkova P; Kolek V; Nakladalova M
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2015 Sep; 159(3):472-9. PubMed ID: 24781044
[TBL] [Abstract][Full Text] [Related]
18. Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment.
Grigoriu BD; Scherpereel A; Devos P; Chahine B; Letourneux M; Lebailly P; Grégoire M; Porte H; Copin MC; Lassalle P
Clin Cancer Res; 2007 May; 13(10):2928-35. PubMed ID: 17504993
[TBL] [Abstract][Full Text] [Related]
19. Retrospective analysis of large-scale research screening of construction workers for the early diagnosis of mesothelioma.
Hirohashi T; Igarashi K; Abe M; Maeda M; Hino O
Mol Clin Oncol; 2014 Jan; 2(1):26-30. PubMed ID: 24649303
[TBL] [Abstract][Full Text] [Related]
20. Comparison of osteopontin, megakaryocyte potentiating factor, and mesothelin proteins as markers in the serum of patients with malignant mesothelioma.
Creaney J; Yeoman D; Demelker Y; Segal A; Musk AW; Skates SJ; Robinson BW
J Thorac Oncol; 2008 Aug; 3(8):851-7. PubMed ID: 18670302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
